Tandem Diabetes Care (TNDM) Shareholder's Equity Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.89% |
| Dec 31, 2025 | -29.35% |
| Sep 30, 2025 | -31.94% |
| Jun 30, 2025 | -33.32% |
| Mar 31, 2025 | -29.19% |
| Dec 31, 2024 | -15.31% |
| Sep 30, 2024 | -15.19% |
| Jun 30, 2024 | -12.25% |
| Mar 31, 2024 | -8.12% |
| Dec 31, 2023 | -5.04% |
| Sep 30, 2023 | -1.30% |
| Jun 30, 2023 | 7.14% |
| Mar 31, 2023 | 17.81% |
| Dec 31, 2022 | 31.16% |
| Sep 30, 2022 | 36.19% |
| Jun 30, 2022 | 45.70% |
| Mar 31, 2022 | 53.49% |
| Dec 31, 2021 | 48.87% |
| Sep 30, 2021 | 50.01% |
| Jun 30, 2021 | 136.98% |
| Mar 31, 2021 | 197.97% |
| Dec 31, 2020 | 144.23% |
| Sep 30, 2020 | 139.16% |
| Jun 30, 2020 | 155.33% |
| Mar 31, 2020 | 383.33% |
| Dec 31, 2019 | 226.78% |
| Sep 30, 2019 | 217.92% |
| Jun 30, 2019 | 65.48% |
| Mar 31, 2019 | 38.08% |
| Dec 31, 2018 | 27.41% |
| Sep 30, 2018 | 17.46% |
| Jun 30, 2018 | -33.33% |
| Mar 31, 2018 | -51.25% |
| Dec 31, 2017 | -36.34% |
| Sep 30, 2017 | -34.15% |
| Jun 30, 2017 | -30.43% |
| Mar 31, 2017 | -26.39% |
| Dec 31, 2016 | -27.06% |